<DOC>
	<DOCNO>NCT00016965</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness BMS-247550 treating patient advance pancreatic cancer .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 6-month survival rate time treatment failure patient advance pancreatic adenocarcinoma treat BMS-247550 . - Determine frequency severity toxic effect drug patient . - Determine complete partial response patient measurable disease treat drug . - Determine pharmacokinetic profile drug patient . OUTLINE : This multicenter study . Patients receive BMS-247550 IV 3 hour day 1 . Courses repeat every 21 day absence unacceptable toxicity disease progression . Patients follow every 6 month 2 year annually 3 year registration . PROJECTED ACCRUAL : A total 25-55 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced pancreatic adenocarcinoma Distant metastases OR Locoregional disease fail amenable locoregional therapy No de novo locoregional disease No known brain metastasis PATIENT CHARACTERISTICS : Age : Adult Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No recent myocardial infarction , unstable angina , lifethreatening arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer remission No prior severe hypersensitivity reaction drug contain Cremophor EL No active uncontrolled infection No severe psychiatric disorder PRIOR CONCURRENT THERAPY : Biologic therapy : No prior neoadjuvant , adjuvant , primary immunotherapy advance pancreatic cancer No concurrent anticancer immunotherapy Chemotherapy : No prior neoadjuvant , adjuvant , primary chemotherapy advance pancreatic cancer No concurrent anticancer chemotherapy Endocrine therapy : No prior neoadjuvant , adjuvant , primary hormonal therapy advance pancreatic cancer No concurrent anticancer hormonal therapy Radiotherapy : No prior neoadjuvant , adjuvant , primary radiotherapy chemoradiotherapy advance pancreatic cancer Prior palliative radiotherapy allow least 1 lesion remains outside radiation field least 1 lesion progress since radiotherapy No concurrent anticancer radiotherapy except palliative radiotherapy nontarget metastatic site Surgery : At least 2 week since prior surgery pancreatic cancer recover Other : No concurrent anticancer therapy No concurrent herbal unconventional therapy ( e.g. , St. John 's Wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>